FDA updates guidance on development of rare disease therapies

FDA has revised its draft guidance for developing rare disease treatments to include the use of biomarkers as surrogate endpoints in

Read the full 212 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE